Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 9, 2006, Pages 1366-1371

  Nathan, Debbie M ^a   Angus, Peter W ^b   Gibson, Peter R ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b AUSTIN HEALTH   (Australia)

^c BOX HILL HOSPITAL   (Australia)

Author keywords

Ankylosing spondylitis; Hepatitis; Inflammatory bowel disease; Reactivation; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ADEFOVIR; AMINOTRANSFERASE; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; NUCLEOSIDE ANALOG; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; CANCER CHEMOTHERAPY; CHRONIC HEPATITIS; ENTERITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; LIVER INJURY; MEDICAL DECISION MAKING; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; TRANSPLANTATION; VIRUS LOAD; VIRUS REACTIVATION;

EID: 33746652902     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04559.x     Document Type: Review

References (41)

1. Ellerin T, Hurtado R, Lockamn S, Baden L. Infections and anti-tumour necrosis factor alpha therapy. Arthritis Rheum. 2003; 48: 3013-22.
2. Walsh MJ, Vanags DM, Clouston AD et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39: 1230-8.
3. Pol S, Zylberberg H, Fontaine H, Brechot C. Treatment of chronic hepatitis C in special groups. J. Hepatol. 1999; 31 (Suppl. 1): 205-9.
4. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001; 19: 65-91.
5. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc. Soc. Exp. Biol. Med. 2000; 223: 241-57.
6. Kasahara S, Ando K, Saito K et al. Lack of tumour necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J. Virol. 2003; 77: 2469-76.
7. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-22.
8. Ahmed A, Keeffe E. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999; 94: 249-51.
9. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000; 62: 299-307.
10. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata El. Severe hepatitis related to chemotherapy in Hepatitis B virus carriers with haematological malignancies. Survey in Japan, 1987-1991. Cancer 1996; 78: 2210-15.
11. Kumagai K, Tagaki T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. 1997; 8 (Suppl. 1): S107-9.
12. Angus PW. Review: hepatitis B and liver transplantation. J. Gastroenterol. Hepatol. 1997; 12: 217-23.
13. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000; 6: 429-33.
14. Ahmed A, Keefe E. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999; 94: 249-51.
15. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann. Oncol. 1998; 9: 385-7.
16. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J. Antimicrob. Chemother. 2005; 55: 828-31.
17. Idilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J. Viral Hepat. 2004; 11: 141-7.
18. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann. Hematol. 2004; 83: 270-5.
19. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
20. Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT. Biomedicines to reduce inflammation but not viral load in chronic HCV: what's the sense? Trends Biotechnol. 2004; 22: 517-23.
21. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol. Cell Biol. 2001; 79: 515-36.
22. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83: 1224-30.
23. Faggioli P, De Paschale M, Tocci A et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997; 82: 38-42.
24. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 1997; 26: 1-5.
25. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996; 334: 815-20.
26. Pavli P, Bayliss GJ, Dent OF, Lunzer MR. The prevalence of serological markers for hepatitis B virus infection in Australian Naval personnel. Med. J. Aust. 1989; 151: 74-5.
27. O'Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust. N. Z. J. Public Health 2004; 28: 212-16.
28. Amin J, Gidding H, Gilbert G et al. Hepatitis C prevalence - a nationwide serosurvey. Commun. Dis. Intel. 2004; 28: 517-21.
29. Biancone L, Pavia M, Del Vecchio Blanco G et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm. Bowel Dis. 2001; 7: 287-94.
30. Longo F, Hebuterne X, Tran A et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol. Clin. Biol. 2000; 24: 77-81.
31. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.
32. Ueno Y, Tanaka S, Shimamoto M et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig. Dis. Sci. 2005; 50: 163-6.
33. Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm. Bowel Dis. 2004; 10: 701-2.
34. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. 2005; 64: 788-9.
35. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis. 2003; 62: 686-7.
36. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J. Rheum. 2003; 30: 1624-5.
37. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol 2001; 13: 191-2.
38. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am. J. Gastroenterol. 2003; 98: 504-5.
39. Parke FA, Reveille JD. Anti-tumour necrosis factor agents for RA in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004; 51: 800-1.
40. Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J. Rheum. 2004; 31: 107-9.
41. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann. Rheum. Dis. 2003; 62: 1078-82.